Diamyd phase 3 type 1 diabetes precision medicine trial receives positive interim analysis

News
Article

Diamyd to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2 was granted Fast Track designation by the FDA in February 2024.

Phase 3 type 1 diabetes precision medicine trial receives positive interim analysis | Image Credit: © Michael O'Neill - © Michael O'Neill - stock.adobe.com.

Phase 3 type 1 diabetes precision medicine trial receives positive interim analysis | Image Credit: © Michael O'Neill - © Michael O'Neill - stock.adobe.com.

The DIAGNODE-3 phase 3 clinical trial (NCT05018585) evaluating rhGAD65/alum (Diamyd; Diamyd Medical) has received a favorable recommendation to continue, without any modifications, from an independent Data Safety Monitoring Board (DSMB) according to a press release from Diamyd Medical.1,2

The interim analysis evaluated data at a 6-month time point from 74 patients enrolled in the trial to assess the likelihood of achieving the preservation of endogenous insulin-producing capacity measured as C-peptide, one of the study's co-primary endpoints. Overall, the trial's objective is to evaluate safety and efficacy of 3 intranodal injections of 4 μg of Diamyd compared to placebo, in addition of oral vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype, according to available study details via ClinicalTrials.gov.1,2

The confirmatory, 2-arm, randomized, double-blind, multicenter, and placebo-controlled trial will enroll up to 330 individuals aged 12 to 29 years who have been diagnosed with type 1 diabetes (T1D) within 6 months and carry the HLA DR3-DQ2 haplotype, a certain genetic risk factor for T1D.1

The patient population in DIAGNODE-3 is based on the clinical results from the phase 2a and phase 2b DIAGNODE-1 (NCT02352974) and DIAGNODE-2 (NCT03345004) trials, in addition to a meta-analysis that included data from more than 600 individuals from previous phase 2 and phase 3 trials using Diamyd.1

"The trial design provides a high probability of reaching its co-primary endpoints of preservation of endogenous insulin-producing capacity measured as stimulated C-peptide and improved blood glucose control as determined by HbA1c," wrote Diamyd in the press release.1

"We are extremely pleased with the DSMB's recommendation to continue the DIAGNODE-3 trial as planned," said Ulf Hannelius, CEO, Diamyd Medical. "This positive outcome reaffirms our confidence in the potential for Diamyd to address an unmet medical need in Type 1 Diabetes. We are committed to advancing this promising therapy as part of a process recently approved by the [FDA], allowing for an accelerated approval pathway for Diamyd. We look forward to achieving our next milestones towards this goal."1

Diamyd to improve glycemic control in recently diagnosed stage 3 T1D patients with the genotype HLA DR3-DQ2 was granted Fast Track designation by the FDA in February 2024.3

References:

  1. Diamyd Medical announces positive interim analysis results for phase 3 trial in type 1 diabetes. Diamyd Medical. Press release. July 30, 2024. Accessed August 1, 2024. https://www.prnewswire.com/news-releases/diamyd-medical-announces-positive-interim-analysis-results-for-phase-3-trial-in-type-1-diabetes-302210231.html
  2. A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes (DIAGNODE-3). ClinicalTrials.gov. Updated July 19, 2024. Accessed August 1, 2024. https://clinicaltrials.gov/study/NCT05018585
  3. Diamyd Medical receives US FDA Fast Track designation for Diamyd. Diamyd Medical. February 15, 2024. Accessed August 1, 2024. https://www.diamyd.com/docs/pressClips.aspx?ClipID=4751158

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Greg Forlenza, MD
Greg Forlenza, MD
Greg Forlenza, MD
Herbert Bravo, MD
Brittany Bruggeman, MD
Brittany Bruggeman, MD
Brittany Bruggeman, MD
Linda DiMeglio, MD, MPH
Related Content
© 2025 MJH Life Sciences

All rights reserved.